Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C8H15NO6.H2O |
| Molecular Weight | 239.2231 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O.CC(=O)N[C@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO
InChI
InChIKey=KVWIBLJBIFTKIZ-XNJRRJNCSA-N
InChI=1S/C8H15NO6.H2O/c1-4(12)9-5(2-10)7(14)8(15)6(13)3-11;/h2,5-8,11,13-15H,3H2,1H3,(H,9,12);1H2/t5-,6-,7-,8-;/m1./s1
DescriptionCurator's Comment: Description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/25962821
Curator's Comment: Description was created based on several sources, including
http://www.ncbi.nlm.nih.gov/pubmed/25962821
N-acetylmannosamine (ManNAc), a hexosamine monosaccharide, is the first committed biological precursor of Neu5Ac. N-acetylmannosamine is being investigated as a potential treatment for GNE myopathy. N-acetylmannosamine has being reported to improve the cognitive function in aged animals. It has potential therapeutic application for cognitive dysfunction. N-acetylmannosamine is under investigation for GNE myopathy.
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2585 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28641925 |
10 g single, oral dose: 10 g route of administration: Oral experiment type: SINGLE co-administered: |
N-ACETYLMANNOSAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
14161 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28641925 |
10 g single, oral dose: 10 g route of administration: Oral experiment type: SINGLE co-administered: |
N-ACETYLMANNOSAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28641925 |
10 g single, oral dose: 10 g route of administration: Oral experiment type: SINGLE co-administered: |
N-ACETYLMANNOSAMINE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
| Dose | Population | Adverse events |
|---|---|---|
10 g single, oral Highest studied dose |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: |
Other AEs: Diarrhea, Nausea... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Nausea | 16.7% | 10 g single, oral Highest studied dose |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: |
| Diarrhea | 50% | 10 g single, oral Highest studied dose |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| No overall hyposialylation in hereditary inclusion body myopathy myoblasts carrying the homozygous M712T GNE mutation. | 2005-03-04 |
|
| Increased biosynthesis of glycosphingolipids in congenital disorder of glycosylation Ia (CDG-Ia) fibroblasts. | 2002-11 |
|
| Synthesis of C-3 nitrogen-containing derivatives of N-acetyl-alpha,beta-D-mannosamine as substrates for N-acetylneuraminic acid aldolase. | 2001-05-18 |
|
| Synthesis of omega-(methoxycarbonyl)alkyl and 9-(methoxycarbonyl)-3,6-dioxanonyl glycopyranosides for the preparation of carbohydrate-protein conjugates. | 1992-06-04 |
|
| Partial purification and properties of neuraminidase from Bifidobacterium lactentis. | 1981-02 |
|
| 2-Acetamidoglucal, a new metabolite isolated from the urine of a patient with sialuria. | 1979-03-22 |
Sample Use Guides
GNE myopathy or hereditary inclusion body myopathy:
liquid solution of N-acetylmannosamine - 3,000 mg, 6,000 mg, and 10,000 mg orally
Route of Administration:
Oral
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/16/1635
Created by
admin on Tue Apr 01 20:55:44 GMT 2025 , Edited by admin on Tue Apr 01 20:55:44 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000183815
Created by
admin on Tue Apr 01 20:55:44 GMT 2025 , Edited by admin on Tue Apr 01 20:55:44 GMT 2025
|
PRIMARY | |||
|
FPD5WTK4TS
Created by
admin on Tue Apr 01 20:55:44 GMT 2025 , Edited by admin on Tue Apr 01 20:55:44 GMT 2025
|
PRIMARY | |||
|
676347-48-1
Created by
admin on Tue Apr 01 20:55:44 GMT 2025 , Edited by admin on Tue Apr 01 20:55:44 GMT 2025
|
PRIMARY | Scifinder | ||
|
22868018
Created by
admin on Tue Apr 01 20:55:44 GMT 2025 , Edited by admin on Tue Apr 01 20:55:44 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
